|May 12, 2014|
|07:54 EDT||GSK, LCI||Lannett announces multi-services agreement with Sunshine Lake|
Lannett Company (LCI) announced that it has entered into distribution and contract manufacturing services agreements with Sunshine Lake LLC, the U.S. subsidiary of the HEC Pharm Group of Shenzhen, Guangdong Province, China. Under terms of the distribution agreement, Lannett will be the exclusive distributor in the U.S. for Sunshine Lake’s Zidovudine generic pharmaceutical product in finished dosage form. Zidovudine Tablets 300 mg was launched by Lannett last week. According to IMS, full year 2013 total sales of Zidovudine Tablets 300 mg, the generic equivalent of Retrovir, a registered trademark of GlaxoSmithKline (GSK), at Average Wholesale Price were approximately $4.5M. The intention of the parties is to add additional products from time to time, and may include a number of ANDAs currently pending at FDA, as well as future filings.
News For LCI;GSK From The Last 14 Days
|June 26, 2015|
|10:38 EDT||GSK||Court revives lawsuit over GlaxoSmithKline Lamictal drug, Bloomberg reports|
Subscribe for More Information
|June 25, 2015|
|14:01 EDT||GSK||GlaxoSmithKline initiated with a Buy at HSBC|
Price target GBP 17.
|June 24, 2015|
|13:37 EDT||GSK||GSK says CDC committee votedfor meningococcal group B vaccines|
GlaxoSmithKline (GSK) announced that the U.S. Centers for Disease Control Advisory Committee on Immunization Practices voted for a Category B recommendation for meningococcal group B vaccination, including Bexsero, in individuals aged 16 to 23. Bexsero was approved by the FDA in January for use in individuals aged 10 through 25 years and acquired by GSK in March following the closure of the three-part transaction with Novartis (NVS).
|June 23, 2015|
|07:25 EDT||GSK||Piper Jaffray to hold a summit|
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
|June 22, 2015|
|07:01 EDT||GSK||Pfizer to acquire Nimenrix, Mencevax from GlaxoSmithKline for $130M|
Pfizer (PFE) announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130M. This transaction will add two high-quality and complementary vaccines to Pfizer’s portfolio, allowing the company to reach a broader global population. Nimenrix is a single dose meningococcal ACWY-TT conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. Mencevax is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers to countries where the disease is endemic or highly epidemic. Pfizer does not expect this transaction to have any significant impact on its 2015 financial performance. The transaction is subject to customary closing conditions as well as regulatory approvals in several markets, and is expected to occur in the second half of 2015. Pfizer’s legal advisors for the transaction were Ropes & Gray and Clifford Chance.
|June 18, 2015|
|13:08 EDT||GSK||GlaxoSmithKline management to meet with Piper Jaffray|
Meeting to be held in Minneapolis on June 23 hosted by Piper Jaffray.
|June 16, 2015|
|13:16 EDT||GSK||FDA appoves labeling changes for GSK anti-seizure drug |
Subscribe for More Information